Sparsentan, a medication, may be a potential new treatment option for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder that can lead to kidney failure. A University of Minnesota Medical School-led study found that FSGS patients treated with sparsentan showed improved kidney function and displayed significant reductions in proteinuria.
Avalon Malware Framework: Advanced Modular Threat Leveraging CrownX Ransomware Targets Windows Systems and Supply Chain Security – Rescana
Avalon Malware Framework: Advanced Modular Threat Leveraging CrownX Ransomware Targets Windows Systems and Supply Chain Security Rescana
